- Home
- Applications
- asia middle east
- pharma to accelerate the development
Show results for
Refine by
Pharma To Accelerate The Development Product Applications Available In In Asia Middle East
6 applications found
Most chemical and pharmaceutical substances have a powdery or mealy consistency. Our well-proven pelleting process is also ideal for the pharmaceutical industry, where it is particularly important to achieve a concentration of active ingredients. Chemical and pharmaceutical pellets facilitate exact ...
ByAmandus Kahl GmbH & Co. KG based in Reinbek, GERMANY
Premium
The pharmaceutical industry includes discovering, developing, producing, and marketing drugs to be used as medications and vaccines to treat and cure patients across the globe. The modern pharmaceutical industry began in the early 1800s and continues to grow rapidly until this day. For example, in 2018, cancer drugs made nearly 100 billion U.S. dollars of revenue ...
ByGalaxy Scientific Inc based in Nashua, NEW HAMPSHIRE (USA)
Researchers have found many uses for MALDI mass spectrometry imaging in the process of drug ...
ByHTX Technologies, LLC based in Chapel Hill,, NORTH CAROLINA (USA)
Formulation is a major component in the efficacy of a drug. Formulation involves the preparation/mixture of an active pharmaceutical ingredient in/with a physical carrier (i.e., a tablet, spray, inhaler, or syrup) to insure adequate efficacy, delivery, and stability. Heavily used in formulation, polymeric excipients such as copovidone (PVP/VA64) can serve various functions when added to API such as matrix former, binding agent or sustained release ...
BySpectra Analysis Instruments, Inc. based in Marlborough, MASSACHUSETTS (USA)
In this example, the aggregation of magnetic nanoparticles labeled with DiR is monitored in real time. Tumor microvasculature is labeled using ...
ByMauna Kea Technologies based in Paris, FRANCE
Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of ...
ByFinch Therapeutics Group, Inc. based in Somerville, MASSACHUSETTS (USA)